Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma

Cancer Science

Volumn 105, Issue 4, 2014, Pages 437-444

  Ichikawa, Satoshi ^a   Fukuhara, Noriko ^a   Katsushima, Hiroki ^a   Takahashi, Taro ^b   Yamamoto, Joji ^c   Yokoyama, Hisayuki ^d   Sasaki, Osamu ^e   Fukuhara, Osamu ^f   Nomura, Jun ^a   Ishizawa, Kenichi ^a   Ichinohasama, Ryo ^g   Muto, Akihiko ^a   Igarashi, Kazuhiko ^a   Harigae, Hideo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Osaki Citizen Hospital   (Japan)

^c SENDAI CITY HOSPITAL   (Japan)

^d SENDAI CITY MEDICAL CENTER   (Japan)

^e Miyagi Cancer Center   (Japan)

^f Sendai Red Cross Hospital   (Japan)

^g NTT East Tohoku Hospital   (Japan)

Author keywords

BACH2; Diffuse large B cell lymphoma; Malignant lymphoma; MYC; Prognostic factors

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BACH2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOGENETICS; FEMALE; GENE MUTATION; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME;

BACH2; DIFFUSE LARGE B-CELL LYMPHOMA; MALIGNANT LYMPHOMA; MYC; PROGNOSTIC FACTORS;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84898479572     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12361     Document Type: Article

References (25)

1. Isaacson PG, Chott A, Ott G, Stein H. Diffuse large B-cell lymphoma, not otherwise specified. In: Stein H, Warnke RA, Chan WC et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC, 2008; 233-7.
2. Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012; 119: 4619-24.
3. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114: 3533-7.
4. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
5. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
6. Benesova K, Forsterova K, Votavova H et al. The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Neoplasma 2013; 60: 68-73.
7. Castillo JJ, Beltran BE, Song MK et al. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res 2012; 36: 413-7.
8. Muto A, Hoshino H, Madisen L et al. Identification of Bach2 as a B-cell-specific partner for small maf proteins that negatively regulate the immunoglobulin heavy chain gene 3′ enhancer. EMBO J 1998; 17: 5734-43.
9. Muto A, Tashiro S, Nakajima O et al. The transcriptional programme of antibody class switching involves the repressor Bach2. Nature 2004; 429: 566-71.
10. Ochiai K, Muto A, Tanaka H, Takahashi S, Igarashi K. Regulation of the plasma cell transcription factor Blimp-1 gene by Bach2 and Bcl6. Int Immunol 2008; 20: 453-60.
11. Muto A, Ochiai K, Kimura Y et al. Bach2 represses plasma cell gene regulatory network in B cells to promote antibody class switch. EMBO J 2010; 29: 4048-61.
12. Swaminathan S, Huang C, Geng H et al. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med 2013; 19: 1014-22.
13. Sakane-Ishikawa E, Nakatsuka S, Tomita Y et al. Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. J Clin Oncol 2005; 23: 8012-7.
14. Kobayashi S, Taki T, Chinen Y et al. Identification of IGHCdelta-BACH2 fusion transcripts resulting from cryptic chromosomal rearrangements of 14q32 with 6q15 in aggressive B-cell lymphoma/leukemia. Genes Chromosom Cancer 2011; 50: 207-16.
15. Tibiletti MG. Specificity of interphase fluorescence in situ hybridization for detection of chromosome aberrations in tumor pathology. Cancer Genet Cytogenet 2004; 155: 143-8.
16. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013; 48: 452-8.
17. Sasaki S, Ito E, Toki T et al. Cloning and expression of human B cell-specific transcription factor BACH2 mapped to chromosome 6q15. Oncogene 2000; 19: 3739-49.
18. Turkmen S, Riehn M, Klopocki E, Molkentin M, Reinhardt R, Burmeister T. A BACH2-BCL2L1 fusion gene resulting from a t(6;20)(q15;q11.2) chromosomal translocation in the lymphoma cell line BLUE-1. Genes Chromosom Cancer 2011; 50: 389-96.
19. Igarashi K, Ochiai K, Muto A. Architecture and dynamics of the transcription factor network that regulates B-to-plasma cell differentiation. J Biochem 2007; 141: 783-9.
20. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol 2004; 173: 1158-65.
21. Tam W, Gomez M, Nie K. Significance of PRDM1beta expression as a prognostic marker in diffuse large B-cell lymphomas. Blood 2008; 111: 2488-9.
22. Muto A, Tashiro S, Tsuchiya H et al. Activation of Maf/AP-1 repressor Bach2 by oxidative stress promotes apoptosis and its interaction with promyelocytic leukemia nuclear bodies. J Biol Chem 2002; 277: 20724-33.
23. Peroja P, Pasanen AK, Haapasaari KM et al. Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma. Exp Hematol Oncol 2012; 1: 2.
24. Tashiro S, Muto A, Tanimoto K et al. Repression of PML nuclear body-associated transcription by oxidative stress-activated Bach2. Mol Cell Biol 2004; 24: 3473-84.
25. Yoshida C, Yoshida F, Sears DE et al. Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1. Blood 2007; 109: 1211-9.